颠覆!控制率达100%!免疫联合疗法新高度,打破实体瘤禁锢,指明抗癌新道路

著名投资机构支持的核酸新药研发公司诚聘技术合伙人!


图片来源:《JAMA Oncology》官网
本文章仅作为前沿知识分享
不构成临床治疗建议
治疗方案制定需咨询临床医生
参考资料:
[1]. Efficacyand Safety of Pembrolizumab in Combination With Bevacizumab and Oral MetronomicCyclophosphamide in the Treatment of Recurrent Ovarian Cancer: A Phase 2Nonrandomized Clinical Trial. JAMA Oncol. 2021 Jan 1;7(1):78-85

赞 (0)